Skip to main content
Top
Published in: European Radiology 2/2005

01-02-2005 | Cardiac

Noninvasive measurements of cardiac high-energy phosphate metabolites in dilated cardiomyopathy by using 31P spectroscopic chemical shift imaging

Authors: A. Hansch, R. Rzanny, J.-P. Heyne, U. Leder, J. R. Reichenbach, W. A. Kaiser

Published in: European Radiology | Issue 2/2005

Login to get access

Abstract

Dilated cardiomyopathy (DCM) is accompanied by an impaired cardiac energy metabolism. The aim of this study was to investigate metabolic ratios in patients with DCM compared to controls by using spectroscopic two-dimensional chemical shift imaging (2D-CSI). Twenty volunteers and 15 patients with severe symptoms (left ventricular ejection fraction, LVEF<30%) and ten patients with moderate symptoms (LVEF>30%) of DCM were investigated. Cardiac 31P MR 2D-CSI measurements (voxel size: 40×40×100 mm3) were performed with a 1.5 T whole-body scanner. Measurement time ranged from 15 min to 30 min. Peak areas and ratios of different metabolites were evaluated, including high-energy phosphates (PCr, ATP), 2,3-diphosphoglycerate (2,3-DPG) and phosphodiesters (PDE). In addition, we evaluated how PCr/ATP ratios correlate with LVEF as an established prognostic factor of heart failure. The PCr/γ-ATP ratio was significantly decreased in patients with moderate and severe DCM and showed a linear correlation with reduced LVEFs. PDE/ATP ratios were significantly increased only in patients with severe DCM as compared to volunteers. Applying 31P MRS with commonly-available 2D-CSI sequences is a valuable technique to evaluate DCM by determining PCr/ATP ratios noninvasively. In addition to reduced PCr/ATP ratios observed in patients suffering from DCM, significantly-increased PDE/ATP ratios were found in patients with severe DCM.
Literature
1.
go back to reference Fatkin D, Graham RM (2002) Molecular mechanisms of inherited cardiomyopathies. Physiol Rev 82:945–980 Fatkin D, Graham RM (2002) Molecular mechanisms of inherited cardiomyopathies. Physiol Rev 82:945–980
2.
go back to reference Bottomley PA (1994) MR spectroscopy of the human heart: the status and the challenges. Radiology 191:593–612 Bottomley PA (1994) MR spectroscopy of the human heart: the status and the challenges. Radiology 191:593–612
3.
go back to reference Ingwall JS (1982) Phosphorus nuclear magnetic resonance spectroscopy of cardiac and skeletal muscles. Am J Physiol 242:729–744 Ingwall JS (1982) Phosphorus nuclear magnetic resonance spectroscopy of cardiac and skeletal muscles. Am J Physiol 242:729–744
4.
go back to reference Schaefer S, Gober J, Valenza M, Karczmar GS, Matson GB, Camacho SA, Botvinick EH, Massie B, Weiner MW (1988) Nuclear magnetic resonance imaging-guided phosphorus-31 spectroscopy of the human heart. J Am Coll Cardiol 12:1449–1455 Schaefer S, Gober J, Valenza M, Karczmar GS, Matson GB, Camacho SA, Botvinick EH, Massie B, Weiner MW (1988) Nuclear magnetic resonance imaging-guided phosphorus-31 spectroscopy of the human heart. J Am Coll Cardiol 12:1449–1455
5.
go back to reference Schaefer S, Massie B, Weiner MW (1989) Magnetic resonance spectroscopy of the heart. Cardiol Clin 7:697–712 Schaefer S, Massie B, Weiner MW (1989) Magnetic resonance spectroscopy of the heart. Cardiol Clin 7:697–712
6.
go back to reference Sandstede JJ (2003) Assessment of myocardial viability by MR imaging. Eur Radiol 13:52–61PubMed Sandstede JJ (2003) Assessment of myocardial viability by MR imaging. Eur Radiol 13:52–61PubMed
7.
go back to reference Schaefer S, Gober JR, Schwartz GG, Twieg DB, Weiner MW, Massie B (1990) In vivo phosphorus-31 spectroscopic imaging in patients with global myocardial disease. Am J Cardiol 65:1154–1161CrossRef Schaefer S, Gober JR, Schwartz GG, Twieg DB, Weiner MW, Massie B (1990) In vivo phosphorus-31 spectroscopic imaging in patients with global myocardial disease. Am J Cardiol 65:1154–1161CrossRef
8.
go back to reference Auffermann W, Chew WM, Wolfe CL, Tavares NJ, Parmley WW, Semelka RC, Donnelly T, Chatterjee K, Higgins CB (1991) Normal and diffusely abnormal myocardium in humans: functional and metabolic characterization with P-31 MR spectroscopy and cine MR imaging. Radiology 179:253–259 Auffermann W, Chew WM, Wolfe CL, Tavares NJ, Parmley WW, Semelka RC, Donnelly T, Chatterjee K, Higgins CB (1991) Normal and diffusely abnormal myocardium in humans: functional and metabolic characterization with P-31 MR spectroscopy and cine MR imaging. Radiology 179:253–259
9.
go back to reference Masuda Y, Tateno Y, Ikehira H, Hashimoto T, Shishido F, Sekiya M, Imazeki Y, Imai H, Watanabe S, Inagaki Y (1992) High-energy phosphate metabolism of the myocardium in normal subjects and patients with various cardiomyopathies—the study using ECG gated MR spectroscopy with a localization technique. Jpn Circ J 56:620–626 Masuda Y, Tateno Y, Ikehira H, Hashimoto T, Shishido F, Sekiya M, Imazeki Y, Imai H, Watanabe S, Inagaki Y (1992) High-energy phosphate metabolism of the myocardium in normal subjects and patients with various cardiomyopathies—the study using ECG gated MR spectroscopy with a localization technique. Jpn Circ J 56:620–626
10.
go back to reference Hardy CJ, Weiss RG, Bottomley PA, Gerstenblith G (1991) Altered myocardial high-energy phosphate metabolites in patients with dilated cardiomyopathy. Am Heart J 122:795–801CrossRef Hardy CJ, Weiss RG, Bottomley PA, Gerstenblith G (1991) Altered myocardial high-energy phosphate metabolites in patients with dilated cardiomyopathy. Am Heart J 122:795–801CrossRef
11.
go back to reference Neubauer S, Krahe T, Schindler R, Horn M, Hillenbrand H, Entzeroth C, Mader H, Kromer EP, Riegger GA, Lackner K et al (1992) 31P magnetic resonance spectroscopy in dilated cardiomyopathy and coronary artery disease. Altered cardiac high-energy phosphate metabolism in heart failure. Circulation 86:1810–1818 Neubauer S, Krahe T, Schindler R, Horn M, Hillenbrand H, Entzeroth C, Mader H, Kromer EP, Riegger GA, Lackner K et al (1992) 31P magnetic resonance spectroscopy in dilated cardiomyopathy and coronary artery disease. Altered cardiac high-energy phosphate metabolism in heart failure. Circulation 86:1810–1818
12.
go back to reference Bottomley PA, Hardy CJ (1992) Proton overhauser enhancements in human cardiac phosphorus NMR spectroscopy at 1.5 T. Magn Reson Med 24:384–390 Bottomley PA, Hardy CJ (1992) Proton overhauser enhancements in human cardiac phosphorus NMR spectroscopy at 1.5 T. Magn Reson Med 24:384–390
13.
go back to reference Loffler R, Sauter R, Kolem H, Haase A, von Kienlin M (1998) Localized spectroscopy from anatomically matched compartments: improved sensitivity and localization for cardiac 31P MRS in humans. J Magn Reson 134:287–299CrossRef Loffler R, Sauter R, Kolem H, Haase A, von Kienlin M (1998) Localized spectroscopy from anatomically matched compartments: improved sensitivity and localization for cardiac 31P MRS in humans. J Magn Reson 134:287–299CrossRef
14.
go back to reference Meininger M, Landschuetz W, Beer M, Seyfarth T, Horn M, Pabst T, Haase A, Hahn D, Neubauer S, von Kienlin M (1999) Concentrations of human cardiac phosphorus metabolites determined by SLOOP 31P NMR spectroscopy. Magn Reson Med 41:657–663 Meininger M, Landschuetz W, Beer M, Seyfarth T, Horn M, Pabst T, Haase A, Hahn D, Neubauer S, von Kienlin M (1999) Concentrations of human cardiac phosphorus metabolites determined by SLOOP 31P NMR spectroscopy. Magn Reson Med 41:657–663
15.
go back to reference Rector TS, Cohn JN (1994) Prognosis in congestive heart failure. Annu Rev Med 45:341–350CrossRef Rector TS, Cohn JN (1994) Prognosis in congestive heart failure. Annu Rev Med 45:341–350CrossRef
16.
go back to reference Schaefer S (1990) Clinical nuclear magnetic resonance spectroscopy: insight into metabolism. Am J Cardiol 66:45–50CrossRef Schaefer S (1990) Clinical nuclear magnetic resonance spectroscopy: insight into metabolism. Am J Cardiol 66:45–50CrossRef
17.
go back to reference Krahe T, Schindler R, Neubauer S, Ertl G, Horn M, Lackner K (1993) 31P-cardio-MR-spectroscopy in myocardial insufficiency. Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 159:64–70 Krahe T, Schindler R, Neubauer S, Ertl G, Horn M, Lackner K (1993) 31P-cardio-MR-spectroscopy in myocardial insufficiency. Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 159:64–70
18.
go back to reference Schindler R, Krahe T, Neubauer S, Hillenbrand H, Entzeroth C, Horn M, Lackner K, Ertl G (1992) The direct measurement of the spin-grid-relaxation times of phosphorus metabolites in the human myocardium. Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 157:452–457 Schindler R, Krahe T, Neubauer S, Hillenbrand H, Entzeroth C, Horn M, Lackner K, Ertl G (1992) The direct measurement of the spin-grid-relaxation times of phosphorus metabolites in the human myocardium. Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 157:452–457
19.
go back to reference Ye Y, Gong G, Ochiai K, Liu J, Zhang J (2001) High-energy phosphate metabolism and creatine kinase in failing hearts: a new porcine model. Circulation 103:1570–1576 Ye Y, Gong G, Ochiai K, Liu J, Zhang J (2001) High-energy phosphate metabolism and creatine kinase in failing hearts: a new porcine model. Circulation 103:1570–1576
21.
go back to reference Neubauer S, Horn M, Cramer M, Harre K, Newell JB, Peters W, Pabst T, Ertl G, Hahn D, Ingwall JS, Kochsiek K (1997) Myocardial phosphocreatine-to-ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy. Circulation 96:2190–2196 Neubauer S, Horn M, Cramer M, Harre K, Newell JB, Peters W, Pabst T, Ertl G, Hahn D, Ingwall JS, Kochsiek K (1997) Myocardial phosphocreatine-to-ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy. Circulation 96:2190–2196
22.
go back to reference van Dobbenburgh JO, Lekkerkerk C, van Echteld CJ, de Beer R (1994) Saturation correction in human cardiac 31P MR spectroscopy at 1.5 T. NMR Biomed 7:218–224 van Dobbenburgh JO, Lekkerkerk C, van Echteld CJ, de Beer R (1994) Saturation correction in human cardiac 31P MR spectroscopy at 1.5 T. NMR Biomed 7:218–224
Metadata
Title
Noninvasive measurements of cardiac high-energy phosphate metabolites in dilated cardiomyopathy by using 31P spectroscopic chemical shift imaging
Authors
A. Hansch
R. Rzanny
J.-P. Heyne
U. Leder
J. R. Reichenbach
W. A. Kaiser
Publication date
01-02-2005
Publisher
Springer-Verlag
Published in
European Radiology / Issue 2/2005
Print ISSN: 0938-7994
Electronic ISSN: 1432-1084
DOI
https://doi.org/10.1007/s00330-004-2504-0

Other articles of this Issue 2/2005

European Radiology 2/2005 Go to the issue